tify the full complement of genes and their variations that influence sensitivity to toxicologic agents.
Use existing environmental cohort studies and clinical drug trials to investigate the impact of genetic variations on variation in response to a wide range of chemical exposures and pharmaceutical therapies.
In addition to understanding the influence of single SNP variations on susceptibility, focus more attention on investigating context-dependent genetic effects (that is, gene-gene interactions as well as interactions with other biologic contexts such as developmental age, sex, and life course factors) that reflect the state of biologic networks underlying response to toxicologic agents.
Develop multigenic and polygenic models of environmental sensitivity to better characterize the continuum of genomic susceptibility to toxicity and to better use genomic information for risk reduction.
Conduct research on the influence of exposure variation, genetic variation, and their interaction in determining epigenetic modification of the human genome.
Better characterize the influence of epigenetic modifications on disease processes that are associated with exposure to toxicologic agents to use this information for risk characterization and risk reduction.